True Bearing Diagnostics has developed TruCAD, the world’s first highly accurate RNA based blood-test, as a diagnostic tool designed to assist with the early-detection of coronary artery disease. At a fraction of the cost of coronary catheterization or nuclear imaging, the Company believes TruCAD is positioned to transform the coronary diagnostics industry. True Bearing was founded in 2015 to extend and commercialize certain research breakthroughs in genomic medicine as developed by the St. Laurent Institute and George Washington University. The Company´s mission is to introduce a collection of RNA-based blood tests that will drastically decrease the costs associated with the early-detection and treatment of multiple diseases. For example, in addition to TruCAD, True Bearing is developing bio-marker panels that it believes will revolutionize the diagnosis of biofilm, appendicitis, pneumonia, and other diseases.